Maalouf Maya, Reddy Akshay J, Mazboudi Pasha, Min Mildred, Rawal Rushil, Curow Casey A, Guirgus Monica E, Abdalnour Danny S, Brahmbhatt Telak, Patel Rakesh
Medicine, California University of Science and Medicine, Colton, USA.
Dermatology, California Northstate University College of Medicine, Elk Grove, USA.
Cureus. 2023 Feb 28;15(2):e35614. doi: 10.7759/cureus.35614. eCollection 2023 Feb.
Squamous cell carcinoma (SCC) is a form of skin cancer that can be treated using a procedure known as Mohs surgery. Mohs surgery is a safe and effective procedure for eliminating SCC. This surgery requires the usage of an analgesic known as lidocaine. Additional anesthetics were also reported to be necessary for this procedure to be conducted in a manner that significantly minimizes patient harm. According to the review, it was found that SCC was treated with lidocaine as a topical analgesic outside of Mohs surgery. This review analyzes the usage of lidocaine in the treatment of SCC. It was also discovered that lidocaine, as an agent, has the potential to slow the progression of SCC, but more research is needed to see if this is truly the case. On average, it was reported that the concentration of lidocaine used in the in vivo studies was significantly higher than that in the in vitro investigations. Further exploration may be needed to verify the conclusions that were based on the analysis of the papers within the review.
鳞状细胞癌（SCC）是一种皮肤癌，可通过一种称为莫氏手术的程序进行治疗。莫氏手术是一种安全有效的消除SCC的程序。该手术需要使用一种名为利多卡因的镇痛药。据报道，还需要额外的麻醉剂才能以显著减少患者伤害的方式进行此程序。根据该综述，发现SCC在莫氏手术之外使用利多卡因作为局部镇痛药进行治疗。本综述分析了利多卡因在SCC治疗中的使用情况。还发现，利多卡因作为一种药物，有可能减缓SCC的进展，但需要更多研究来确定情况是否确实如此。据报道，体内研究中使用的利多卡因浓度平均显著高于体外研究中的浓度。可能需要进一步探索以验证基于综述中论文分析得出的结论。
